This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berthold, D. R. Articles by Tannock, I. F. Search for Related Content PubMed PubMed Citation Articles by Berthold, D. R. Articles by Tannock, I. F. Social Bookmarking                            What's this?

Management of Advanced Prostate Cancer After First-Line Chemotherapy

Dominik R. Berthold, Cora N. Sternberg, Ian F. Tannock

From the Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Canada; and the Division of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy

Address reprint requests to Ian F. Tannock MD, PhD, FRCPC, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada; e-mail: Ian.Tannock{at}uhn.on.ca.

Hormone refractory prostate cancer (HRPC) causes substantial morbidity and mortality. There are increasing options for both first- and second-line therapy in the palliative treatment of patients with HRPC. Medications to control symptoms should first be optimized in patients with late-stage disease, and radiotherapy applied to dominant painful bone lesions. Docetaxel, mitoxantrone, satraplatin, and ixabepilone are active chemotherapeutic agents in the first- and/or second-line setting for patients with HRPC, and this may be true also of older drugs such as oral cyclophosphamide and vinorelbine. Radioisotopes such as strontium and samarium are useful for treatment of more generalized bone pain. Third-line hormonal maneuvers including glucocorticoids, ketoconazole, and estrogens can lead to further palliation in some patients, and there are provocative data that chemotherapy might restore hormonal sensitivity in a subset of patients.

D.R.B. is supported by a Prostate Cancer Research Training Grant to Princess Margaret Hospital from the Canadian Prostate Cancer Research Initiative.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. R. Berthold, G. R. Pond, R. de Wit, M. Eisenberger, I. F. Tannock, and On behalf of the TAX 327 investigators Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa Ann. Onc., October 1, 2008; 19(10): 1749 - 1753. [Abstract] [Full Text] [PDF]

				K. W. Yip, X. Mao, P.Y. B. Au, D. W. Hedley, S. Chow, S. Dalili, J. D. Mocanu, C. Bastianutto, A. Schimmer, and F.-F. Liu Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen. Clin. Cancer Res., September 15, 2006; 12(18): 5557 - 5569. [Abstract] [Full Text] [PDF]

				E. J. Small and E. A. Klein Challenges and Future Directions in the Prevention and Management of Prostate Cancer J. Clin. Oncol., November 10, 2005; 23(32): 8143 - 8145. [Full Text] [PDF]